October 11, 2013 - Video: Eric Johnson, Professor of Bacteriology, University of Wisconsin-Madison, USA Read More>>>

Video: Eric Johnson, Professor of Bacteriology, University of Wisconsin-Madison, USA

Video: 

http://productrecall.fonterra.com/en/video-eric-johnson,-professor-of-bacteriology,-university-of-wisconsin-madison,-usa/

Transcript: 

Interview transcript: Eric Johnson, Professor of Bacteriology, University of Wisconsin-Madison, USA (13 August, 2013)

I’m Eric Johnson a professor at University of Wisconsin, Madison. I became interested in clostridium Botulinum when I was studying at MIT in Harvard where I worked on clostridia, and then I went to University of Wisconsin in the mid 1980’s.

I have worked on clostridium Botulinum for nearly thirty years; I am an expert in the field. My laboratory and my research studies fundamental as well as basic aspects of the organism, the pathogen and its potent neurotoxins.

University of Wisconsin has a rich history of studying clostridium Botulinum mostly from a food botulism perspective.

Clostridium Botulinum is a spore-forming organism and spores are highly resistant forms of the organism that are spread worldwide. And traditionally the spores have been known to cause food poisoning where they get into the food and they’ll produce toxin, and the toxin they produce is the most poisonous substance known and people traditionally have consumed that and come down with foodborne botulism.

Infant botulism was discovered in the mid 1970’s by which the spores get into a baby’s intestine under one year old and the spores are able to germinate and produce toxin in the intestine and cause botulism in the child. It’s extraordinarily rare. In the United States about 70% of the cases occur which is 70-100 per year and so worldwide there are probably less than 150 cases of hospitalized infant botulism.

Clostridium Botulinum spores are prevalent in every region of the world so most people are exposed likely on a daily basis including infants actually dust and things other than food are probably the most common route of spore ingestion.

There’s four main types of clostridium Botulinum around the world. The third type comprising of a certain group of toxins are found in New Zealand and those do not cause human botulism they cause botulism in animals primarily and birds.

In New Zealand I know of only one case of botulism since botulism was discovered in the 1970’s.

Clostridium Botulinum is present in the environment, as I mentioned, and many foods do become contaminated with the spores. Most of these foods are vegetables and associated foods that contact the soil. The number of spores in infant formula is either non-existent or extraordinarily few and so the likelihood of getting infant botulism from infant formula is extremely rare in fact there are no cases known of babies developing botulism from infant formula.

The spores have been found in formula. It is rare. Many surveys have been done and most of the surveys show that clostridium Botulinum is not in infant formula however it is possible that the spores are there but they’re at such low concentrations because milk has, it’s been estimated, one spore per litre and so the levels of spores are extremely low and the number of spores in a food correlates with the likelihood of coming down with the illness.

The number of spores to cause botulism is not known, but based on honey studies it is thought to be as low as perhaps ten spores on ingestion up to much more – a hundred spores or more.

So in infant formula the number of spores generally are much lower than the dose required to lead to disease.

When a children becomes ill, typically it does not defecate for several days. It is constipated, but that is not a definitive symptom. The definitive symptom invariably involves your cranial nerves that [innovate] your eyes, and so blurred vision and maybe symptosis or sagging of the face and also a general malaise and weakness of the child: its suck, its cry are weakened compared to what you see as your normal, healthy child. And these children should be brought to a doctor, preferably a neurologist, and also their serum and their fecal matter should be examined for the presence of Botulinum toxin ‘cause that would provide a definitive diagnosis.

The treatment is very careful nursing care where most of the children who enter hospital do not have difficulty breathing. They’re there for a period of a few weeks. Some develop severe infant botulism where the toxin will descend and cause paralysis of your respiratory ability and in those cases the children will be put on a respirator. There’s been very few children, you can count them on your both hands, that have actually succumbed or died from infant botulism. So with proper nursing care they will survive. The toxin does not enter into your brain, your CNS, and so it is not known to have any permanent damage.

Now there were two infant botulism cases which I was involved with and one of the scientists who handles children with botulism, he tested formula that was being fed to those infants that had botulism and clostridium Botulinum spores were not found in the infant formula. And so as I’ve mentioned in the past, environmental sources are the normal route of infection and so the testing that is done strongly indicates that the environment, as opposed to the food, is the source of the spores.

There are no foods to my knowledge that are routinely tested. It requires considerable time and there would be so many non-existent or negative results that in my view it would not be practical to test foods for the presence of spores of clostridium Botulinum.

You test for clostridium Botulinum by its route of intoxication which involves absorption into the blood and then trafficking to the nerve, binding to a receptor, internalization into the nerve and cleavage of a [substrain]. That takes quite a long period, so the only test that will follow all those steps of intoxication currently is the mouse bioassay which is very expensive, uses a number of animals but it’s a very sensitive assay. There are other assays being developed including one in my lab where you use neuronal cells to test for the toxin but right now that is the only definitive test.

The mouse bioassay involves isolating the spores from a food, growing them in a culture medium for the bacterium, for clostridium Botulinum, taking that culture medium and injecting mice intraperitoneally and then observing them for typical signs of botulism and eventually death. However that is not conclusive of botulism unless you add antibodies specifically to the toxin to neutralize it and if the mice then survive, that is the definitive diagnosis of botulism.

Clostridium Botulinum is a very poor competitor with other organisms in foods and the intestine and so that is the reason that only very young children can get it because the competitive organisms are not present in their intestinal tract.

To identify the strains of clostridium Botulinum there are seven main serotypes. Only three of those cause botulism those three serotypes are not found in New Zealand. However to identify the serotype of the of the seven, you would inject a mouse and then you would neutralize with serotype-specific antibodies. So in other words if there is botulism in an individual and you use antibodies to Type A, when injected the mouse will survive it will no longer die from that.

There are other methods that have been used but they are not definitive such as heating an extract that has been lethal to a mouse, and this is in fact what was done in this case, to this point, but that is not definitive for a diagnosis of botulism because there are many heat [liable] substances in foods.

The testing method of sulfite reduction on ager is a general test that identifies organisms that reduce sulfur to a component that is readily detectable on ager plates. It is produced by a large variety of organisms and it is not specific to clostridium Botulinum. So it can indicate high levels of different organisms that can cause mainly spoilage in food.

In my candid opinion the sulfite reduction rest for organisms in milk powder or other foods is valuable for testing for potential spoilage but is not valuable for pathogens especially toxigenic clostridia such as clostridium Botulinum.

The diagnosis for botulism is detecting the toxin. It’s the toxin that is solely responsible for the disease. It is not the organism, unlike other diseases like salmonellosis or other pediatric diseases and so detection of the toxin is the only definitive proof and at this time that has not been accomplished.

I think Fonterra have been careful and have taken the right steps in trying to reassure the public, especially I guess parents of infants that the disease is extraordinarily rare and that if symptoms are observed and fortunately they have not been, to my knowledge in any cases, then they will be treated with proper medical care.

In order to move forward in view of this presumptive incident I feel that there should be assurance within a plant – a dairy plant – that spores of Botulinum are extremely rare. However I do not feel based on epidemiology and the methods required that routine testing will be of value in diagnosis of potential foods that could cause botulism.

I admire Fonterra for being proactive in this incident without having evidence that the sulfite-reducing organisms that were detected were clostridium Botulinum, as I’ve mentioned that’s a general test that tests a number of different clostridia. However this was complimented by a mouse bioassay where the mice were injected and one of the several injected did have a fatality. But antibodies were not available at the time so that test could have detected many lethal substances in food in which in my own laboratory we find are extremely common. So in essence, the proactive of Fonterra bringing this to the community and the general public and dairy organizations is appropriate.

At this time there is no conclusive proof of the tests and reports that have been disseminated that botulism is an issue in this incident and that is being tested now by a laboratory that I know very well – the Centre for Disease Control – and they will have a definitive test, but at this time it should not be concluded that botulism is associated with this incident.

Very simply it’s extraordinarily rare and has been virtually non-existent in the dairy industry.

June 4, 2013 - Wisconsin State Journal: Eric A. Johnson: Health threat of raw milk should be focus, not retail legislation. Read More>>>

It is surprising the debate on the sale of raw milk has centered on retail legislation when the real threat is transmission of disease.

Pasteurization of raw milk over many decades has led to the decreased incidence of certain human illnesses including brucellosis, tuberculosis, listeriosis and many other human life-threatening diseases.

The Centers for Disease Control and Prevention has estimated globally that raw milk is responsible for nearly three times more hospitalizations than any other food-borne source. Raw milk-associated diseases are particularly important in immuno-compromised sectors of the human population including the very young, elderly, pregnant women and patients with underlying diseases such as AIDS.

If the sale of raw milk continues to be permitted, it is only a matter of time until severe diseases are again transmitted in this food. In the meantime, it is a major concern that other dairy farms will begin to see a niche to sell raw milk that will further increase the incidence of milk-borne diseases.

-- Eric A. Johnson, professor, Department of Bacteriology, UW-Madison College of Agricultural and Life Sciences



Read more: Wisconsin State Journal

February 3, 2012 - Neurons From Stem Cells Could Replace Mice In Botulinum Test Read More>>>

MADISON - Using lab-grown human neurons, researchers from the University of Wisconsin-Madison have devised an effective assay for detecting botulinum neurotoxin, the agent widely used to cosmetically smooth the wrinkles of age and, increasingly, for an array of medical disorders ranging from muscle spasticity to loss of bladder control.

 

The new assay uses neurons, the critical impulse conducting cells of the central nervous system, derived from induced human pluripotent stem cells. It is the first test to employ stem cell derivatives to reliably and quantitatively detect botulinum neurotoxin and the antibodies that can neutralize the toxin's effects.

 

The assay is likely to draw considerable interest from industry as a potential replacement for the mouse, an animal now used by the thousands to control the potency of pharmaceutical preparations of the powerful neurotoxin.

 

Using cells provided by Madison-based Cellular Dynamics International, a company that industrially manufactures induced pluripotent stem cells and their derivative tissue cells for use in research and industry, the University of Wisconsin-Madison team devised an assay that is more sensitive than the mouse assay required for quality control of pharmaceutical preparations of botulinum toxin.

 

'This is an optimal testing platform for botulinum neurotoxin products,' explains Sabine Pellett who, with UW-Madison professor of bacteriology Eric A. Johnson, led the new study published this week in the journal Toxicological Sciences. 'A cell-based assay that is at least as sensitive and reproducible as the mouse bioassay can serve as a viable alternative and largely eliminate the need to use animals.'

 

The toxin is used most famously for cosmetic purposes to erase the facial wrinkles that come with age. However, it is also used in a growing number of medical applications. Since it was first approved in 1990 for use in human patients with strabismus or cross-eye, the toxin, which works by blocking communication between nerves and muscles, has been used to successfully treat excessive sweating, chronic migraine headaches, painful neck spasms known as dystonia, and muscle conditions associated with cerebral palsy, multiple sclerosis and stroke. In 2010, the Food and Drug Administration (FDA) approved the toxin for use in treating loss of bladder control. Pharmaceutical applications of the toxin underpin a market that easily exceeds $1 billion annually.

 

Botulinum toxin is a protein produced by the bacterium Clostridium botulinum. It is the most potent toxin known to science and before its first experimental medical application to treat cross-eye was best known as a food poison. The methods to produce the toxin in large quantities and to precise specifications were pioneered at UW-Madison by Johnson and his late mentor, Ed Schantz.

 

Because of its incredible potency, the quality and dosages of the toxin for medical use must be carefully prepared.

 

The preparations made by pharmaceutical companies, says Johnson, actually contain very little toxin. To ensure that batches of the agent are of the correct therapeutic dose and of uniform quality, they are tested by injecting mice at a specified dosage that kills half of all mice exposed to the toxin.

 

'The mouse assay has many drawbacks and hundreds of thousands of mice are used for this every year,' Pellett explains. 'The most important result of this study is the high sensitivity of the assay, greater than the mouse bioassay, which is required for quality control.'

 

The pharmaceutical industry, Johnson adds, is under pressure from the FDA to develop alternatives to the mouse. One cell-based assay has already been developed by Allergan, the company that makes BOTOX, the most famous trade name for botulinum toxin. However, the details of that assay have not been made available.

 

'The assay we developed is another cell based assay,' notes Pellett, 'one that uses normal human neurons derived from induced pluripotent stem cells, and which can be optimized for any pharmaceutical botulinum neurotoxin product.'

 

In addition to Pellett and Johnson, authors of the new study include Regina Whitemarsh and William H. Tepp, of UW-Madison; and Monica. J. Strathman, Lucas G. Chase and Casey Stankewicz of Cellular Dynamics International. The study was funded by the U.S. National Institutes of Health.

December 1, 2011 - Evaluating the safety of microbial enzyme preparations used in food processing: update for a new century. Read More>>>

Microbial enzymes used in food processing are typically sold as enzyme preparations that contain not only a desired enzyme activity but also other metabolites of the production strain, as well as added materials such as preservatives and stabilizers.


The added materials must be food grade and meet applicable regulatory standards. The purpose of this report is to present guidelines that can be used to evaluate the safety of the metabolites of the production strain that are also present in the enzyme preparation, including of course, but not limited to, the desired enzyme activity itself.


This discussion builds on previously published decision tree mechanisms and includes consideration of new genetic modification technologies, for example, modifying the primary structure of enzymes to enhance specific properties that are commercially useful. The safety of the production strain remains the primary consideration in evaluating enzyme safety, in particular, the toxigenic potential of the production strain.


Thoroughly characterized nonpathogenic, nontoxigenic microbial strains, particularly those with a history of safe use in food enzyme manufacture, are logical candidates for generating a safe strain lineage, through which improved strains may be derived via genetic modification by using either traditional/classical or rDNA strain improvement strategies.


The elements needed to establish a safe strain lineage include thoroughly characterizing the host organism, determining the safety of all new DNA that has been introduced into the host organism, and ensuring that the procedure(s) that have been used to modify the host organism are appropriate for food use.


Enzyme function may be changed by intentionally altering the amino acid sequence (e.g., protein engineering). It may be asked if such modifications might also affect the safety of an otherwise safe enzyme. We consider this question in light of what is known about the natural variation in enzyme structure and function and conclude that it is unlikely that changes which improve upon desired enzyme function will result in the creation of a toxic protein.


It is prudent to assess such very small theoretical risks by conducting limited toxicological tests on engineered enzymes. The centerpiece of this report is a decision tree mechanism that updates previous enzyme safety evaluation mechanisms to accommodate advances in enzymology.


We have concluded that separate mutagenicity testing is not needed if this decision tree is used to evaluate enzyme safety. Under the criteria of the decision tree, no new food enzyme can enter the market without critical evaluation of its safety.

September 1, 2004 - Single-cell microbiology: tools, technologies, and applications. Read More>>>

The field of microbiology has traditionally been concerned with and focused on studies at the population level. Information on how cells respond to their environment, interact with each other, or undergo complex processes such as cellular differentiation or gene expression has been obtained mostly by inference from population-level data.

 

Individual microorganisms, even those in supposedly 'clonal' populations, may differ widely from each other in terms of their genetic composition, physiology, biochemistry, or behavior. This genetic and phenotypic heterogeneity has important practical consequences for a number of human interests, including antibiotic or biocide resistance, the productivity and stability of industrial fermentations, the efficacy of food preservatives, and the potential of pathogens to cause disease.

 

New appreciation of the importance of cellular heterogeneity, coupled with recent advances in technology, has driven the development of new tools and techniques for the study of individual microbial cells. Because observations made at the single-cell level are not subject to the 'averaging' effects characteristic of bulk-phase, population-level methods, they offer the unique capacity to observe discrete microbiological phenomena unavailable using traditional approaches. As a result, scientists have been able to characterize microorganisms, their activities, and their interactions at unprecedented levels of detail.

Patents - List of patents. Read More>>>

 

P Number Title Country Name Status Filing Date Serial Number Publication Date Publication Number Issue Date Patent Number
P00282US METHOD OF TARGETING PHARMACEUTICALS TO MOTOR NEURONS UNITED STATES ISSUED 5/30/2001 09/870262 8/7/2003 US-2003-0147921 12/30/2003 6670322
P01121US HYBRID BOTULINAL NEUROTOXINS UNITED STATES ISSUED 11/3/2000 09/706047     9/3/2002 6444209
P02398US PNA PROBES, PROBE SETS, METHODS AND KITS PERTAINING TO THE DETERMINATION OF LISTERIA UNITED STATES FILED 5/13/2002 10/436962        
P04467US METHOD OF PREPARING BOTULINUM NEUROTOXIN TYPE A LIGHT CHAIN UNITED STATES ISSUED 4/14/2006 11/404289 11/16/2006   12/16/2008 7465457
P05066US PHARMACEUTICAL COMPOSITION CONTAINING BOTULINUM B COMPLEX UNITED STATES ISSUED 10/3/1994 08/316820     12/9/1997 5696077
P06126US DEVICE AND METHODS FOR LIQUID CRYSTAL-BASED BIOAGENT DETECTION UNITED STATES ISSUED 10/31/2006 11/555103 10/4/2007 US-2007-0231832 3/22/2011 7910382
P06126US02 DEVICE AND METHODS FOR LIQUID CRYSTAL-BASED BIOAGENT DETECTION UNITED STATES FILED 1/21/2011 13/011514 7/28/2011 US-2011-0183357    
P06269US PLASMIC-ENCODED NEUROTOXIN GENES IN CLOSTRIDIUM BOTULINUM SEROTYPE A SUBTYPES UNITED STATES FILED 6/29/2007 12/664800 12/9/2010 US-2010-0311118    
P07412US METHOD OF DETECTING BOTULINUM NEUROTOXIN AND ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXIN ACTION UNITED STATES FILED 11/10/2008 12/291411        
P08309US ESCHERICHIA COLI-DERIVED VACCINE AND THERAPY AGAINST BOTULISM UNITED STATES ISSUED 2/29/2008 12/040542 1/15/2009 US-2009-0017495 10/26/2010 7820411
P09050US02 A NOVEL SUBTYPE OF CLOSTERIDIUM BOTULINUM NEUROTOXIN TYPE A AND USE THEREOF UNITED STATES FILED 4/29/2010 12/769754 7/14/2011 US-2011-0171226    
P09079US02 NONTOXIGENIC CLOSTRIDIUM BOTULINUM STRAINS AND USES THEREOF UNITED STATES FILED 8/31/2009 12/550692 5/6/2010 US-2010-0112149    
P09171US METHOD OF PREPARING BOTULINUM NEUROTOXIN TYPE E LIGHT CHAIN UNITED STATES ISSUED 11/18/2008 12/273157 7/16/2009 US-2009-0182123 11/16/2010 7833524
P100091US02 CONJUGATIVE PLASMIDS AND METHODS OF USE THEREOF UNITED STATES FILED 10/15/2010 12/905592 7/14/2011 US-2011-0171734    
P110348US01 PURIFICATION, CHARACTERIZATION AND USE OF CLOSTRIDIUM BOTULINUM NEUROTOXIN BoNT/A3 UNITED STATES FILED 9/28/2011 61/540321        
P94051US PHARMACEUTICAL COMPOSITION OF BOTULINUM NEUROTOXIN AND METHOD OF PREPARATION UNITED STATES ISSUED 10/13/1994 08/322624     4/30/1996 5512547
P95168US HYBRID BOTULINAL NEUROTOXINS UNITED STATES ISSUED 10/28/1996 08/739477     8/17/1999 5939070
P95242US PHARMACEUTICAL COMPOSITIONS OF BOTULINUM TOXIN OR BOTULINUM NEUROTOXIN AND METHODS OF PREPARATION UNITED STATES ISSUED 3/27/1996 08/624771     5/26/1998 5756468
P96019US PURIFICATION OF TYPE G BOTULINUM NEUROTOXIN AND PHARMACEUTICAL COMPOSITIONS THEREOF UNITED STATES ISSUED 4/16/1996 08/633092     12/8/1998 5846929
P97017US CHIMERIC TOXINS UNITED STATES ISSUED 3/14/2000 09/524841     4/8/2003 6545126
P97137US METHOD OF SENSITIZING MICROBIAL CELLS TO ANTIMICROBIAL COMPOUNDS UNITED STATES ISSUED 6/22/1998 09/102466     11/20/2001 6319958
P98171US EXPRESSION SYSTEM FOR CLOSTRIDIUM SPECIES UNITED STATES ISSUED 4/6/1998 09/056075     9/21/1999 5955368
P100091WO01 CONJUGATIVE PLASMIDS AND METHODS OF USE THEREOF W.I.P.O. (IS PCT) FILED 10/15/2010 PCT/US2010/052863 4/21/2011 WO2011/047274    
P06269AU01 PLASMID-ENCODED NEUROTOXIN GENES IN CLOSTRIDIUM BOTULINUM SEROTYPE A SUBTYPES AUSTRALIA FILED 6/27/2008 2008270020        
P05066CA PHARMACEUTICAL COMPOSITION CONTAINING BOTULINUM B COMPLEX CANADA ISSUED 6/22/1993       2/16/1999 2138020
P06269CA01 NOVEL BOTULINUM NEUROTOXIN TYPE A SUBTYPES FOR PHARMACEUTICAL USE CANADA FILED 6/27/2008 2691825        
P09050CA01 A NOVEL SUBTYPE OF CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A AND USE THEROF CANADA FILE OPENED 4/30/2010          
P95242CA PHARMACEUTICAL COMPOSITIONS OF BOTULINUM TOXIN OR BOTULINUM NEUROTOXIN AND METHODS OF PREPARATION CANADA ISSUED 9/16/1996 2250251     11/6/2001 2250251
P06269EP01 NOVEL BOTULINUM NEUROTOXIN TYPE A SUBTYPES FOR PHARMACEUTICAL USE EUROPEAN PATENT OFFICE FILED 6/27/2008 08772138.7 3/31/2010 2167532    
P09050EP01 A NOVEL SUBTYPE OF CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A AND USE THEROF EUROPEAN PATENT OFFICE FILED 4/30/2010 10718786.6        
P95242FR PHARMACEUTICAL COMPOSITIONS OF BOTULINUM TOXIN OR BOTULINUM NEUROTOXIN AND METHODS OF PREPARATION FRANCE ISSUED 9/16/1996 96933019.0     12/12/2001 0889730
P95242DE PHARMACEUTICAL COMPOSITIONS OF BOTULINUM TOXIN OR BOTULINUM NEUROTOXIN AND METHODS OF PREPARATION GERMANY ISSUED 9/16/1996 96933019.0     12/12/2001 P69618018.9
P95242GB PHARMACEUTICAL COMPOSITIONS OF BOTULINUM TOXIN OR BOTULINUM NEUROTOXIN AND METHODS OF PREPARATION GREAT BRITAIN ISSUED 9/16/1996 96933019.0     12/12/2001 0889730
P95242IE PHARMACEUTICAL COMPOSITIONS OF BOTULINUM TOXIN OR BOTULINUM NEUROTOXIN AND METHODS OF PREPARATION IRELAND ISSUED 9/16/1996 96933019.0     12/12/2001 0889730
P05066JP PHARMACEUTICAL COMPOSITION CONTAINING BOTULINUM B COMPLEX JAPAN FILED 6/22/1993 06-502542        
P95242JP PHARMACEUTICAL COMPOSITIONS OF BOTULINUM TOXIN OR BOTULINUM NEUROTOXIN AND METHODS OF PREPARATION JAPAN ISSUED 9/16/1996 09-534359 1/8/2003   11/1/2002 3364658
P06269NZ01 NOVEL BOTULINUM NEUROTOXIN TYPE A SUBTYPES FOR PHARMACEUTICAL USE NEW ZEALAND FILED 6/27/2008 582087        

Published Works - List of published works. Read More>>>

Henkel JS, Tepp WH, Przedpelski A, Fritz RB, Johnson EA, Barbieri JT. 2011. Subunit vaccine efficacy against Botulinum neurotoxin subtypes. Vaccine 29(44):7688-95 (PMC3209516)

Sun S, Suresh S, Liu H, Tepp WH, Johnson EA, Edwardson JM, Chapman ER. 2011. Receptor binding enables botulinum neurotoxin B to sense low pH for translocation channel assembly. Cell Host Microbe 10(3):237-47(PMC3243646)

Jacobson MJ, Lin G, Tepp W, Dupuy J, Stenmark P, Stevens RC, Johnson EA. 2011. Purification, modeling, and analysis of botulinum neurotoxin subtype A5 (BoNT/A5) from Clostridium botulinum strain A661222. Appl. Environ. Microbiol. 77(12):4217-22 (PMC3131645)

Pfender WF, Saha MC, Johnson EA, Slabaugh MB. 2011. Mapping with RAD (restriction-site associated DNA) markers to rapidly identify QTL for stem rust resistance in Lolium perenne. Theor. Appl. Genet. 122(8):1467-80

Etter PD, Preston JL, Bassham S, Cresko WA, Johnson EA. 2011. Local de novo assembly of RAD paired-end contigs using short sequencing reads. PLoS ONE 6(4):e18561 (PMC3076424)

Peng L, Tepp WH, Johnson EA, Dong M. 2011. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog. 7(3):e1002008 (PMC3068998)

Marshall KM, Bradshaw M, Johnson EA. 2010. Conjugative botulinum neurotoxin-encoding plasmids in Clostridium botulinum. PLoS ONE 5(6):e11087 (PMC2884020)

Nakai Y, Pellett S, Tepp WH, Johnson EA, Janda KD. 2010. Toosendanin: synthesis of the AB-ring and investigations of its anti-botulinum properties (Part II). Bioorg. Med. Chem. 18(3):1280-7 (PMC2819598)

Lin G, Tepp WH, Pier CL, Jacobson MJ, Johnson EA. 2010. Expression of the Clostridium botulinum A2 neurotoxin gene cluster proteins and characterization of the A2 complex. Appl. Environ. Microbiol. 76(1):40-7 (PMC2798633)

Bradshaw M, Marshall KM, Heap JT, Tepp WH, Minton NP, Johnson EA. 2010. Construction of a nontoxigenic Clostridium botulinum strain for food challenge studies. Appl. Environ. Microbiol. 76(2):387-93 (PMC2805223)

Helenius IT, Krupinski T, Turnbull DW, Gruenbaum Y, Silverman N, Johnson EA, Sporn PH, Sznajder JI, Beitel GJ.2009. Elevated CO2 suppresses specific Drosophila innate immune responses and resistance to bacterial infection. Proc. Natl. Acad. Sci. U.S.A. 106(44):18710-5 (PMC2773965)

Trott DL, Yang M, Gonzalez J, Larson AE, Tepp WH, Johnson EA, Cook ME. 2009. Egg yolk antibodies for detection and neutralization of Clostridium botulinum type A neurotoxin. J. Food Prot. 72(5):1005-11

Henkel JS, Jacobson M, Tepp W, Pier C, Johnson EA, Barbieri JT. 2009. Catalytic properties of botulinum neurotoxin subtypes A3 and A4. Biochemistry 48(11):2522-8 (PMC2701208)

Nakai Y, Tepp WH, Dickerson TJ, Johnson EA, Janda KD. 2009. Function-oriented synthesis applied to the anti-botulinum natural product toosendanin. Bioorg. Med. Chem. 17(3):1152-7 (PMC2661763)

Zhou H, Zhou B, Pellett S, Johnson EA, Janda KD. 2009. Selection and characterization of a human monoclonal neutralizing antibody for Clostridium Botulinum neurotoxin serotype B. Bioorg. Med. Chem. Lett. 19(3):662-4(PMC2645068)

Iyer AV, Blinkova AL, Yang SY, Harrison M, Tepp WH, Jacobson MJ, Johnson EA, Bennett GN, Walker JR. 2008. Clostridium taeniosporum is a close relative of the Clostridium botulinum Group II. Anaerobe 14(6):318-24

Jacobson MJ, Lin G, Whittam TS, Johnson EA. 2008. Phylogenetic analysis of Clostridium botulinum type A by multi-locus sequence typing. Microbiology (Reading, Engl.) 154(Pt 8):2408-15 (PMC2562668)

Raphael BH, Luquez C, McCroskey LM, Joseph LA, Jacobson MJ, Johnson EA, Maslanka SE, Andreadis JD. 2008. Genetic homogeneity of Clostridium botulinum type A1 strains with unique toxin gene clusters. Appl. Environ. Microbiol. 74(14):4390-7 (PMC2493146)

Jacobson MJ, Lin G, Raphael B, Andreadis J, Johnson EA. 2008. Analysis of neurotoxin cluster genes in Clostridium botulinum strains producing botulinum neurotoxin serotype A subtypes. Appl. Environ. Microbiol. 74(9):2778-86 (PMC2394882)

Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, Johnson EA, Barbieri JT. 2008. Subunit vaccine against the seven serotypes of botulism. Infect. Immun. 76(3):1314-8 (PMC2258812)

Marshall KM, Bradshaw M, Pellett S, Johnson EA. 2007. Plasmid encoded neurotoxin genes in Clostridium botulinum serotype A subtypes. Biochem. Biophys. Res. Commun. 361(1):49-54 (PMC2346372)

Kale RR, Clancy CM, Vermillion RM, Johnson EA, Iyer SS. 2007. Synthesis of soluble multivalent glycoconjugates that target the Hc region of botulinum neurotoxin A. Bioorg. Med. Chem. Lett. 17(9):2459-64

Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, Jackson PJ, Marks JD. 2007. Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J. Bacteriol. 189(3):818-32 (PMC1797315)

Arndt JW, Jacobson MJ, Abola EE, Forsyth CM, Tepp WH, Marks JD, Johnson EA, Stevens RC. 2006. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J. Mol. Biol. 362(4):733-42

An GH, Cho MH, Johnson EA. 2005. Monocyclic carotenoid biosynthetic pathway in the yeast Phaffia rhodozyma (Xanthophyllomyces dendrorhous). J. Biosci. Bioeng. 88(2):189-93

Baldwin MR, Tepp WH, Pier CL, Bradshaw M, Ho M, Wilson BA, Fritz RB, Johnson EA, Barbieri JT. 2005. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect. Immun. 73(10):6998-7005 (PMC1230911)

Brehm-Stecher BF, Hyldig-Nielsen JJ, Johnson EA. 2005. Design and evaluation of 16S rRNA-targeted peptide nucleic acid probes for whole-cell detection of members of the genus Listeria. Appl. Environ. Microbiol. 71(9):5451-7(PMC1214657)

Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, Marks JD. 2005. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect. Immun. 73(9):5450-7 (PMC1231122)

Johnson EA, Tepp WH, Bradshaw M, Gilbert RJ, Cook PE, McIntosh ED. 2005. Characterization of Clostridium botulinum strains associated with an infant botulism case in the United Kingdom. J. Clin. Microbiol. 43(6):2602-7(PMC1151885)

Bradshaw M, Dineen SS, Maks ND, Johnson EA. 2004. Regulation of neurotoxin complex expression in Clostridium botulinum strains 62A, Hall A-hyper, and NCTC 2916. Anaerobe 10(6):321-33

Dong M, Tepp WH, Johnson EA, Chapman ER. 2004. Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc. Natl. Acad. Sci. U.S.A. 101(41):14701-6 (PMC522023)

Brehm-Stecher BF, Johnson EA. 2004. Single-cell microbiology: tools, technologies, and applications. Microbiol. Mol. Biol. Rev. 68(3):538-59 (PMC515252)

Baldwin MR, Bradshaw M, Johnson EA, Barbieri JT. 2004. The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability. Protein Expr. Purif. 37(1):187-95

Glass KA, Johnson EA. 2004. Antibotulinal activity of process cheese ingredients. J. Food Prot. 67(8):1765-9

Glass KA, Johnson EA. 2004. Factors that contribute to the botulinal safety of reduced-fat and fat-free process chesse products. J. Food Prot. 67(8):1687-93

Puhar A, Johnson EA, Rossetto O, Montecucco C. 2004. Comparison of the pH-induced conformational change of different clostridial neurotoxins. Biochem. Biophys. Res. Commun. 319(1):66-71

Dineen SS, Bradshaw M, Karasek CE, Johnson EA. 2004. Nucleotide sequence and transcriptional analysis of the type A2 neurotoxin gene cluster in Clostridium botulinum. FEMS Microbiol. Lett. 235(1):9-16

Echavarri-Erasun C, Johnson EA. 2004. Stimulation of astaxanthin formation in the yeast Xanthophyllomyces dendrorhous by the fungus Epicoccum nigrum. FEMS Yeast Res. 4(4-5):511-9

Brehm-Stecher BF, Johnson EA. 2003. Sensitization of Staphylococcus aureus and Escherichia coli to antibiotics by the sesquiterpenoids nerolidol, farnesol, bisabolol, and apritone. Antimicrob. Agents Chemother. 47(10):3357-60(PMC201169)

Johnson EA, Phaff HJ. 2003. Phaffia rhodozyma: colorful odyssey. Int. Microbiol. 6(3):169-74

Dineen SS, Bradshaw M, Johnson EA. 2003. Neurotoxin gene clusters in Clostridium botulinum type A strains: sequence comparison and evolutionary implications. Curr. Microbiol. 46(5):345-52

Compton SR, Ball-Goodrich LJ, Zeiss CJ, Johnson LK, Johnson EA, Macy JD. 2003. Pathogenesis of mouse hepatitis virus infection in gamma interferon-deficient mice is modulated by co-infection with Helicobacter hepaticus. Comp. Med. 53(2):197-206

Peck RF, Johnson EA, Krebs MP. 2002. Identification of a lycopene beta-cyclase required for bacteriorhodopsin biogenesis in the archaeon Halobacterium salinarum. J. Bacteriol. 184(11):2889-97 (PMC135044)

Goodnough MC, Oyler G, Fishman PS, Johnson EA, Neale EA, Keller JE, Tepp WH, Clark M, Hartz S, Adler M. 2002. Development of a delivery vehicle for intracellular transport of botulinum neurotoxin antagonists. FEBS Lett. 513(2-3):163-8

Johnson EA, Bradshaw M. 2001. Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon 39(11):1703-22

Pariza MW, Johnson EA. 2001. Evaluating the safety of microbial enzyme preparations used in food processing: update for a new century. Regul. Toxicol. Pharmacol. 33(2):173-86

Jacoby RO, Ball-Goodrich L, Paturzo FX, Johnson EA. 2001. Prevalence of rat virus infection in progeny of acutely or persistently infected pregnant rats. Comp. Med. 51(1):38-42

Johnson EA, Evron Y, McCarty RE. 2001. Resonance energy transfer between tryptophan 57 in the epsilon subunit and pyrene maleimide labeled gamma subunit of the chloroplast ATP synthase. Biochemistry 40(6):1804-11

Dineen SS, Bradshaw M, Johnson EA. 2000. Cloning, nucleotide sequence, and expression of the gene encoding the bacteriocin boticin B from Clostridium botulinum strain 213B. Appl. Environ. Microbiol. 66(12):5480-3 (PMC92486)

Jacoby RO, Johnson EA, Paturzo FX, Ball-Goodrich L. 2000. Persistent rat virus infection in smooth muscle of euthymic and athymic rats. J. Virol. 74(24):11841-8 (PMC112467)

Malizio CJ, Goodnough MC, Johnson EA. 2000. Purification of Clostridium botulinum type A neurotoxin. Methods Mol. Biol. 145:27-39

Johnson EA. 1999. Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu. Rev. Microbiol. 53:551-75

Larson AE, Johnson EA, Nelson JH. 1999. Survival of Listeria monocytogenes in commercial cheese brines. J. Dairy Sci. 82(9):1860-8

Maksymowych AB, Reinhard M, Malizio CJ, Goodnough MC, Johnson EA, Simpson LL. 1999. Pure botulinum neurotoxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade. Infect. Immun. 67(9):4708-12 (PMC96798)

Larson AE, Johnson EA. 1999. Evaluation of botulinal toxin production in packaged fresh-cut cantaloupe and honeydew melons. J. Food Prot. 62(8):948-52

Glass KA, Kaufman KM, Smith AL, Johnson EA, Chen JH, Hotchkiss J. 1999. Toxin production by Clostridium botulinum in pasteurized milk treated with carbon dioxide. J. Food Prot. 62(8):872-6

Bradshaw M, Goodnough MC, Johnson EA. 1998. Conjugative transfer of the Escherichia coli-Clostridium perfringens shuttle vector pJIR1457 to Clostridium botulinum type A strains. Plasmid 40(3):233-7

Angulo FJ, Getz J, Taylor JP, Hendricks KA, Hatheway CL, Barth SS, Solomon HM, Larson AE, Johnson EA, Nickey LN, Ries AA. 1998. A large outbreak of botulism: the hazardous baked potato. J. Infect. Dis. 178(1):172-7

Shek WR, Paturzo FX, Johnson EA, Hansen GM, Smith AL. 1998. Characterization of mouse parvovirus infection among BALB/c mice from an enzootically infected colony. Lab. Anim. Sci. 48(3):294-7

Ball-Goodrich LJ, Leland SE, Johnson EA, Paturzo FX, Jacoby RO. 1998. Rat parvovirus type 1: the prototype for a new rodent parvovirus serogroup. J. Virol. 72(4):3289-99 (PMC109804)

Glass KA, Kaufman KM, Johnson EA. 1998. Survival of bacterial pathogens in pasteurized process cheese slices stored at 30 degrees C. J. Food Prot. 61(3):290-4

Johnson EA, Lin WJ, Zhou YT, Bradshaw M. 1997. Characterization of neurotoxin mutants in Clostridium botulinum type A. Clin. Infect. Dis. 25 Suppl 2:S168-70

Gu WL, An GH, Johnson EA. 1997. Ethanol increases carotenoid production in Phaffia rhodozyma. J. Ind. Microbiol. Biotechnol. 19(2):114-7

Schantz EJ, Johnson EA. 1997. Botulinum toxin: the story of its development for the treatment of human disease. Perspect. Biol. Med. 40(3):317-27

Leyer GJ, Johnson EA. 1997. Acid adaptation sensitizes Salmonella typhimurium to hypochlorous acid. Appl. Environ. Microbiol. 63(2):461-7 (PMC168336)

Larson AE, Yu RR, Lee OA, Price S, Haas GJ, Johnson EA. 1996. Antimicrobial activity of hop extracts against Listeria monocytogenes in media and in food. Int. J. Food Microbiol. 33(2-3):195-207

Hutson RA, Zhou Y, Collins MD, Johnson EA, Hatheway CL, Sugiyama H. 1996. Genetic characterization of Clostridium botulinum type A containing silent type B neurotoxin gene sequences. J. Biol. Chem. 271(18):10786-92

Johnson EA, Schroeder WA. 1996. Microbial carotenoids. Adv. Biochem. Eng. Biotechnol. 53:119-78

Lin WJ, Johnson EA. 1995. Genome analysis of Clostridium botulinum type A by pulsed-field gel electrophoresis. Appl. Environ. Microbiol. 61(12):4441-7 (PMC167752)

Leyer GJ, Wang LL, Johnson EA. 1995. Acid adaptation of Escherichia coli O157:H7 increases survival in acidic foods. Appl. Environ. Microbiol. 61(10):3752-5 (PMC167674)

Schroeder WA, Johnson EA. 1995. Singlet oxygen and peroxyl radicals regulate carotenoid biosynthesis in Phaffia rhodozyma. J. Biol. Chem. 270(31):18374-9

Jacoby RO, Johnson EA, Ball-Goodrich L, Smith AL, McKisic MD. 1995. Characterization of mouse parvovirus infection by in situ hybridization. J. Virol. 69(6):3915-9 (PMC189117)

Gaertner DJ, Jacoby RO, Johnson EA, Paturzo FX, Smith AL. 1995. Persistent rat virus infection in juvenile athymic rats and its modulation by immune serum. Lab. Anim. Sci. 45(3):249-53

Zhou Y, Sugiyama H, Nakano H, Johnson EA. 1995. The genes for the Clostridium botulinum type G toxin complex are on a plasmid. Infect. Immun. 63(5):2087-91 (PMC173270)

 

Files & Info:

 

Confidentiality Agreement:
Confidentiality for use with Legal Consultation.
Download PDF >>>

Press Release:
Neurons From Stem Cells Could Replace Mice In Botulinum Test. Download Word Doc >>>

Journal Publications & Bio:
Education, Positions, Awards, and Journal Publications List.
Download Word Doc >>>

Patents:
List of filed and issued patents.
Download Spreadsheet >>>